Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

EST Altimmune (ALT) files $400M mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 20% growth forecast for the ...

William Blair analyst Andy Hsieh initiated coverage of Altimmune (ALT) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...

Altimmune, Inc. announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso, who bring extensive experience in the biopharmaceutical industry.

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are currently covering the stock, MarketBeat reports. One equities research ...

Altimmune (NASDAQ:ALT – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th.Analysts expect the company to announce earnings ...

Altimmune Inc (ALT) reports a strong cash position and promising trial developments, despite increased expenses and ...

Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. (Operator Instructions) I ...